Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment, and you are unlikely to be protected if something goes wrong.
Take two mins to learn more
Proven leadership: Led by biotech veteran Richard Vellacott - track record in scaling and exiting high-growth companies.
Large addressable market and high growth: Targeting cell & gene therapy in a biotech sector growing at 13.9% CAGR globally.
Novel technology: 3D-printed biocomputer platform - scalable, flexible, and a step-change in automation.
Strong traction: Deals with large corporates and a growing commercial pipeline.
High-return potential: Clear exit paths via strategic buyers or private equity.

